References
- Barnes BE. Dermatomyositis and malignancy. Ann Intern Med 1976;84:68–76.
- Callen JP. Myositis and malignancy. Clin Rheum Dis 1984;10:117–30.
- Iwatsuki K, Xu Z, Ohtsuka M, Kaneko F. Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview. J Dermatol Sci 2000;22:181–95.
- Kanavaros P, Lescs MC, Briere J, Divine M, Galateau F, Joab I, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993;81:2688–95.
- Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, et al. Nasal T-cell lymphoma causally associated with Epstein-Barr virus. Clinicopathogenic, phenotypic, and genotypic studies. Cancer 1996;77:2137–40.
- Endo T, Kawaguchi N, Yashima M, Tei H, Hayakawa H. Polymyositis-dermatomyositis and Non-Hodgkin's lymphoma. Int Med 1993;32(6):487–9.
- Antonioli CM, Airo P. Dermatomyositis associated with lymphoproliferative disorder of NK cells and occult small cell lung carcinoma. Ftheumatol Clin Immunol 2004;23(3)238–41.
- Ohtsuka M, Iwatsuki K, Kaneko R, Akiba H, Kikuchi S, Harada H, et al. Epstein-Barr virus-associated lymphoid hyperplasia of the eyelid characterized by intramuscular infiltration. Br J Dermatol 1999;140:358–77.
- Shirasaki K, Taniuchi K, Matsushita T, Hamaguchi Y, Tanaka M, Takehara K. Epstein-Barr virus-associated T-cell lymphoma: a case of eyelid swelling and intramuscular infiltration mimicking dermatomyositis. Br J Dermatol 2002;147:1244–8.
- Okano M. Epstein-Barr virus infection and its role in the expand-ing spectrum of human diseases. Acta Paediatr 1998;87:11–8.
- Tokugawa M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. Epstein-Barr virus in gastric carcinoma. Am J Pathol 1993;143:1250–4.
- Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47,883–9.
- Ohga S, Nomura A, Takada H. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001;183:1–7.
- Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al. Induction of bc1-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65: 1107–15.
- Hudnall SD, Ge Y, Wei L, Yang NP, Wang HQ, Chen T. Distribu-tion and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol 2005;18(4):519–27.
- Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders; disease spectrum, pathogenesis and management, Leuk Lymphoma 1995;19:401–6.
- Okamura T, Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet 2000;356:223–4.
- Uehara T, Nakaseko C, Hara S, Harima A, Ejiri M, Yokota A, et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a pa-tient with the lethal form of chronic active EBV infection. Am J Hematol 2004;76(4):368–72.
- Koizumi K, Fujimoto K, Haseyama Y, Endo T, Nishio M, Yokota K, et al. Effective high-dose chemotherapy combined with CD34*-selected peripheral blood stem cell transplantation in a patient with cutaneous involvement of nasal NK/T-cell lymphoma. Eur J Haematol 2004;72:140–4.